Mesenchymal to epithelial transition in sarcomas

Abstract Mesenchymal to epithelial transition (MET) in carcinomas has been proposed to promote the growth of epithelial tumour cells at distant sites during metastasis. MET has also been suggested as an important biological and clinical process in mesenchymal tumors, sarcomas. Here we review studies...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2014-02, Vol.50 (3), p.593-601
Main Authors: Yang, Jilong, Du, Xiaoling, Wang, Guowen, Sun, Yan, Chen, Kexin, Zhu, Xiongzeng, Lazar, Alexander J.F, Hunt, Kelly K, Pollock, Raphael E, Zhang, Wei
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Biomarkers, Tumor - metabolism
Cell Differentiation - physiology
E-cadherin
Epithelial differentiation
Epithelial-Mesenchymal Transition
Hematology, Oncology and Palliative Medicine
Humans
Medical sciences
Mesenchymal to epithelial transition
Micro RNA
MicroRNAs - genetics
MicroRNAs - metabolism
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Pharmacology. Drug treatments
Sarcoma
Sarcoma - genetics
Sarcoma - metabolism
Sarcoma - pathology
Targeted therapy
Transcriptional factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mesenchymal to epithelial transition (MET) in carcinomas has been proposed to promote the growth of epithelial tumour cells at distant sites during metastasis. MET has also been suggested as an important biological and clinical process in mesenchymal tumors, sarcomas. Here we review studies on MET in sarcomas, including molecular markers, signalling mechanisms, regulation by micro RNAs and therapeutic implications. Accumulating evidences suggest that deeper investigation and understanding of MET in sarcomas would shed light on the pathogenesis of sarcomas and might lead to identification of potential clinical biomarkers for prognosis and targets for sarcoma therapeutics.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2013.11.006